Market Intelligence

Access the latest earnings reports, market analysis, hot topics, and individual stock insights

Report Categories

View All

Recent Articles

View All
US Stock Markets Advance as Tech Gains and USIran Talks Boost Investor Sentiment AMD Announces Over 10 Billion Investment in Taiwans AI Semiconductor Ecosystem Traders Debate Potential Shift Away from Quarterly Earnings Reporting BlackBerry Leverages Malaysia as Strategic Hub for Asia Cybersecurity Expansion UKGulf Trade Deal Hailed as Monumental Achievement by Bahrain Minister FFWM Q4 2025 Earnings Significant EPS Miss Amidst Challenging Environment RFIL Q1 2026 Earnings Strong EPS Surprise Drives Share Gains Despite Limited Revenue Disclosure AD Q1 2026 Earnings Significant EPS Beat Driven by Operational Efficiency LUXE Q1 2026 Earnings EPS Miss Weighs on Sentiment as Revenue Data Remains Withheld INDI Q1 2026 Earnings EPS Slightly Misses Estimates but Stock Surges on Investor Optimism First Hawaiian Inc FHB Edges Higher Amid Consolidation Support and Resistance Levels in Focus Camping World Holdings CWH Shows Resilience Nears Key Resistance Level NAPCO Security Technologies NSSC Slips 197 as Stock Tests Key Support Levels Upbound Group Inc UPBD Moves Higher Testing NearTerm Resistance Meituan Shares Plunge to TwoYear Low as Layoff Denial Fails to Assuage Investor Concerns Guzman y Gomez Exits US Market Citing Competitive Pressures Kevin Warsh Faces Divisive Fed Over Rate Cut Debate as Inflation and Yields Surge Powell Warsh Set for Historic FOMC Overlap as Fed Transitions Leadership AMR Q1 2026 Earnings Metallurgical Coal Producer Posts Unexpected Loss as Earnings Miss Estimates by Wide Margin CHYM Q1 2026 Earnings Strong EPS Surprise of 2768 Despite Modest Stock Decline GMHS Q1 2026 Earnings Positive EPS Marks a Turnaround Quarter Stock Jumps 656 GWAV Q3 2023 Earnings Significant Loss Per Share Amidst Operational Challenges Grindr Q4 2025 Earnings EPS Misses Estimates Amid Operational Adjustments SELLAS Life Sciences Group SLS Q1 2026 Earnings WiderthanExpected Loss as PreRevenue Biotech Focuses on Pipeline Progress